Winners of Bio-IT World’s 2008 Best Practices Awards Honored



By Bio-IT World Staff

May 6, 2008 | Bio-IT World has announced the winners of its fourth Best Practices Awards program. The awards ceremony took place April 29, 2008, at the World Trade Center in Boston and was co-located with CHI’s Sixth Annual Bio-IT World Conference & Expo.

Grand Prize winners within seven life sciences awards categories include Applied Biosystems, Christian-Albrechts-University, Eli Lilly & Company, GlaxoSmithKline, Genstruct, Sirtris Pharmaceuticals, AstraZeneca, and Merck & Company. 

In addition, this year’s recipient of the Editor’s Choice Award is Dr. Kenneth H. Buetow, NCI Associate Director for Bioinformatics and Information Technology, for the implementation of caBIG, an open source network to speed cancer research. 
 
The ceremony featured keynote speeches by Colin Hill, CEO, president, chairman & co-Founder of Gene Network Sciences; and Dietrich Stephan, Ph.D., co-founder and chief science officer of Navigenics, former deputy director, Translational Genomics Research Institute. 

Phillips Kuhl, co-founder and president of Cambridge Healthtech Institute (CHI), started the evening with welcoming comments and introduced Kevin Davies, Ph.D., editor-in-chief of Bio-IT World, the flagship publication of CHI, to initiate the presentation of awards.

“Bio-IT World salutes the winners of its 2008 Best Practices Awards program. Not only have they demonstrated impressive technical achievements as judged by their peers, but also they’ve demonstrated a commitment to advancing “best practices” throughout the biomedical research and drug development community by their willingness to share information about the innovative tools they are using and explaining how they use them,” said Kevin Davies, editor in chief of Bio-IT World.

A peer-review panel of 14 expert judges reviewed 54 detailed submissions from organizations ranging from large pharmaceutical and biotechnology companies, academic institutions, to niche service providers, detailing best practices in one of seven categories. John Russell, executive editor of Bio-IT World; Rudy Potenzone, Ph.D., WW industry technology strategist for pharmaceuticals of Microsoft; James Reaney, director, research markets of BlueArc Corporation; and Kevin Davies, Bio-IT World, presented the Grand Prize trophies to the following organizations within these categories:

• Basic Research, R&D:  Christian-Albrechts-University and Applied Biosystems
These organizations were recognized for developing a pipeline to use for the identification of common susceptibility variants of functional significance for complex diseases, notably Crohn’s disease.

• Clinical Research:  Eli Lilly & Company
The organization was recognized for managing and tracking metrics associated with implementing the SAS Drug Development solution / partnership.

• Clinical Trials:  GlaxoSmithKline
GSK was recognized for developing a novel industry capability which enables robust and efficient safety signal detection in clinical trials from phase 1 onward.

• Drug Discovery & Development:  Genstruct and Sirtris Pharmaceuticals
Both organizations were recognized for developing a Casual Network Modeling (CNM) system—a powerful approach to modeling complex biological systems. Sirtris and Genstruct collaborated to characterize the molecular MOA of a revolutionary set of bioactive, Sirt1—activating small molecules.

• IT Informatics:  AstraZeneca Pharmaceuticals
The organization was recognized for implementing the FDA’s electronic submissions gateway with SAFE digital signatures. 

• Knowledge Management:  AstraZeneca Discovery (UK)
The organization was recognized for standardizing screening data globally and making it available to all AstraZeneca sites.

• Translational and Personalized Medicine:  Merck & Company
The organization was recognized for breaking down clinical and research silos that allowed them to view the Biomarker Information Pipeline with the Moffitt Cancer Center that automates the flow and integration of patient care data and gene expression data. 

Honorable recognition also went to the following organizations in the seven categories:

• Basic Research, R&D:  University of Pittsburgh Cancer Institute
• Clinical Research:  National Institute of Neurological Disorders & Stroke
• Clinical Trials:  Johnson & Johnson PRD Early Development
• Drug Discovery & Development:  GlaxoSmithKline
• IT Informatics:  River Road Bio
• Knowledge Management:  Naval Medical Research Center
• Translational and Personalized Medicine:  Cogenics and IO Informatics

Learn more about the Bio-IT World Best Practices Awards program.

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .